Table 5. Subgroup analyses of ORR, DCR and QIR between the experimental and control group.
| Parameter | Factors at study level | Experimental group No. of patients (n) |
Control group No. of patients (n) |
Analysis method | Heterogeneity | Risk ratio (RR) | 95% CI | P-value | |
|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | P-value | ||||||||
| ORR | Tumor types | ||||||||
| OC | 885 | 810 | Fixed | 0 | 0.91 | 2.34 | 1.89–2.90 | <0.00001 | |
| CC | 280 | 225 | Random | 51 | 0.08 | 2.55 | 1.35–4.80 | 0.004 | |
| EC | 34 | 34 | Fixed | Not applicable | 2.96 | 1.10–7.94 | 0.03 | ||
| Study types | |||||||||
| RCT | 963 | 900 | Fixed | 0 | 0.95 | 2.58 | 2.09–3.19 | <0.00001 | |
| Non-RCT | 283 | 214 | Fixed | 40 | 0.15 | 1.91 | 1.32–2.78 | 0.0006 | |
| Dosage of Aidi injection | |||||||||
| =50 ml/day | 506 | 496 | Fixed | 0 | 0.98 | 2.66 | 2.01–3.52 | <0.00001 | |
| >50 ml/day | 469 | 447 | Fixed | 0 | 0.48 | 2.30 | 1.70–3.10 | <0.00001 | |
| Study sample size | |||||||||
| ≥60 | 960 | 835 | Fixed | 0 | 0.58 | 2.28 | 1.85–2.82 | <0.00001 | |
| <60 | 286 | 279 | Fixed | 0 | 0.87 | 2.80 | 1.93–4.05 | <0.00001 | |
| DCR | Tumor types | ||||||||
| OC | 637 | 618 | Fixed | 0 | 0.93 | 2.69 | 1.93–3.75 | <0.00001 | |
| CC | 221 | 166 | Fixed | 0 | 0.52 | 1.86 | 1.11–3.13 | 0.02 | |
| EC | 34 | 34 | Fixed | Not applicable | 4.31 | 1.07–17.39 | 0.04 | ||
| Study types | |||||||||
| RCT | 740 | 680 | Fixed | 0 | 0.93 | 2.77 | 2.02–3.81 | <0.00001 | |
| Non-RCT | 184 | 168 | Fixed | 0 | 0.44 | 2.13 | 1.31–3.45 | 0.002 | |
| Dosage of Aidi injection | |||||||||
| 50 ml/day | 381 | 374 | Fixed | 0 | 0.99 | 2.86 | 1.81–4.53 | <0.00001 | |
| >50 ml/day | 430 | 408 | Fixed | 6 | 0.39 | 2.58 | 1.82–3.67 | <0.00001 | |
| Study sample size | |||||||||
| ≥60 | 653 | 584 | Random | 0 | 0.75 | 2.57 | 1.91–3.45 | <0.00001 | |
| <60 | 271 | 264 | Random | 0 | 0.85 | 2.57 | 1.42–4.63 | 0.002 | |
| QIR | Tumor types | ||||||||
| OC | 531 | 512 | Fixed | 0 | 0.81 | 3.71 | 2.84–4.85 | <0.00001 | |
| CC | 136 | 112 | Fixed | 0 | 0.73 | 3.18 | 1.86–5.43 | <0.0001 | |
| EC | 30 | 28 | Fixed | Not applicable | 2.46 | 0.80–7.63 | 0.12 | ||
| Study types | |||||||||
| RCT | 612 | 585 | Fixed | 0 | 0.93 | 3.56 | 2.77–4.57 | <0.00001 | |
| Non-RCT | 142 | 122 | Fixed | 0 | 0.40 | 3.56 | 2.13–5.95 | <0.00001 | |
| Dosage of Aidi injection | |||||||||
| 50 ml/day | 272 | 261 | Fixed | 0 | 1.00 | 2.90 | 2.02–4.17 | <0.00001 | |
| >50 ml/day | 427 | 399 | Fixed | 0 | 0.62 | 4.14 | 3.06–5.61 | <0.00001 | |
| Study sample size | |||||||||
| ≥60 | 488 | 449 | Fixed | 0 | 0.61 | 3.39 | 2.57–4.48 | <0.00001 | |
| <60 | 266 | 258 | Fixed | 0 | 0.98 | 3.89 | 2.66–5.70 | <0.00001 | |
Notes: Control group: conventional treatments alone group; Experimental group: conventional treatments and Aidi injection combined group.
Abbreviations: DCR: disease control rate; ORR: overall response rate; QIR: quality of life improved rate.